Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats

European Journal of Clinical Investigation

Volumn 33, Issue 11, 2003, Pages 1006-1012

  Heller, J ^a   Shiozawa, T ^a   Trebicka, J ^a   Hennenberg, M ^a   Schepke, M ^a   Neef, M ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Angiotensin; Cirrhosis; Losartan; Portal hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETER; ARTICLE; BILIARY CIRRHOSIS; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMORAL ARTERY; HEMODYNAMIC MONITORING; HEMODYNAMICS; INTRAVENOUS CATHETER; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERFUSION PRESSURE; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRESSURE GRADIENT; PRIORITY JOURNAL; RAT; SHUNTING; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIAC OUTPUT; HEMODYNAMIC PROCESSES; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; LOSARTAN; MALE; MICROSPHERES; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE;

EID: 0242721933     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01251.x     Document Type: Article

References (35)

1. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958;24:358-67.
2. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Sem Liv Dis 1999;19:359-81.
3. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-9.
4. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56.
5. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-5.
6. González-Abraldes J, Albillos A, Bañares R, Del Arbol LR, Moitinho E, Rodriguez C et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121:382-8.
7. Debernardi-Venon W, Barletti C, Alessandria C, Marzano A, Baroni M, Todros L et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002;47:401-4.
8. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY et al. Effect of 1-week losartan administration on bile duct ligated cirrhotic rats with portal hypertension. J Hepatol 2002;36:600-6.
9. Lee SS, Giroud C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effects of pentobarbital sodium. Am J Physiol 1986;251:G176-80.
10. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305-11.
11. Van de Casteele M, Sägesser H, Zimmermann H, Reichen J. Characterization of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Therap 2001;90:35-43.
12. Lebrec D. Animal models in portal hypertension. In: Okuda K, Benhamou JP, editors. Portal Hypertension: Clinical and Physiological Aspects. Tokyo: Springer-Verlag; 1991. pp. 101-13.
13. Thomas SH, Joh T, Benoit JN. Role of bile acids in splanchnic hemodynamic response to chronic portal hypertension. Dig Dis Sci 1991;36:1243-8.
14. Genecin P, Polio J, Colombato LA, Ferrailoli G, Reuben A, Groszmann RJ. Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. Am J Physiol 1990;259:G21-5.
15. Seyde WC, Longnecker DE. Anesthetic influence on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology 1984;61:686-98.
16. Kojima H, Yamao J, Tsujimoto T, Uemura M, Takaya A, Fukui H. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43-50.
17. Hakkinen JP, Miller MW, Smith AH, Knight DR. Measurement of organ blood flow with colored microspheres in the rat. Cardiovasc Res 1995;29:74-9.
18. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portosystemic shunting in experimental portal hypertension. Am J Physiol 1989;257:G52-7.
19. D'Almeida MS, Cailmail S, Lebrec D. Validation of transit-time ultrasonic flow probes to directly measure portal flow in conscious rats. Am J Physiol 1996;271:H2701-9.
20. Lebrec D, Poynard T, Hilon P, Benhamou JP. Propranolol for prevention of gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981;305:1371-4.
21. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
22. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991;324:1532-8.
23. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M et al. Hemodynamic events in a prospective randomized clinical trial of propranolol versus placebo in the prevention of first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
24. Garcia-Tsao G, Grace ND, Groszmann RJ. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;1:101-6.
25. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002;37:773-80.
26. Ramalho LN, Ramalho FS, Zucoloto S, Castro-e-Silva Junior O, Correa FM, Elias Junior J et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 2002;49:1499-502.
27. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Sauerbruch T. Low dose losartan reduces portal pressure, improves kidney function and vascular contractility in cirrhotic rats without affecting arterial pressure. J Hepatol 2002;36:A53.
28. Kroeger RJ, Groszmann RJ. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology 1985;5:425-30.
29. Vaziri ND, Wang XQ, Ni ZN, Kivlighn S, Shahinfar S. Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. Biochim Biophys Acta 2002;1592:153-61.
30. Zhou XJ, Vaziri ND, Zhang J, Wang HW, Wang XQ. Association of renal injury with nitric oxide deficiency in aged SHR. Prevention by hypertension control with AT1 blockade. Kidney Int 2002;62:914-21.
31. Diep QN, El Mabrouk M, Yue P, Schiffrin EL. Effect of AT (1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2002;282:H1635-41.
32. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-López F, Ródes J. Effect of angiotensin-II blockade on systemic and hepatic hemodynamics and on renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981;11:221-9.
33. Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology 1999;117:740-2.
34. Wong F, Liu P, Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002;35:1449-58.
35. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997;74:181-94.